Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
暂无分享,去创建一个
O. Decaux | C. Sebban | P. Moreau | F. Magrangeas | S. Minvielle | H. Avet-Loiseau | C. Mathiot | T. Facon | J. Harousseau | M. Attal | L. Campion | B. Corront | P. Lenain | C. Hulin | B. Lioure | T. Lamy | M. Michallet | L. Legros | F. Malard | J. Fuzibet
[1] P. Moreau,et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] B. Barlogie,et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. , 2010, Blood.
[3] B. Pégourié,et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.
[4] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[5] Serge Leyvraz,et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.
[6] R. Bataille,et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. , 2006, Blood.
[7] L. Staudt,et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. , 2004, Cancer cell.
[8] M. Rue,et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.
[9] I. Hanamura,et al. Ectopic Expression of MAFB Gene in Human Myeloma Cells Carrying (14;20)(q32;q11) Chromosomal Translocations , 2001, Japanese journal of cancer research : Gann.
[10] E. Schröck,et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. , 1998, Blood.